Go to
current issue
-
Health effects from climate-driven events: lessons learnt Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-16
No Abstract
-
Evidence-based personalised medicine in critical care: a framework for quantifying and applying individualised treatment effects in patients who are critically ill Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-15 Elizabeth S Munroe, Alexandra Spicer, Andrea Castellvi-Font, Ann Zalucky, Jose Dianti, Emma Graham Linck, Victor Talisa, Martin Urner, Derek C Angus, Elias Baedorf-Kassis, Bryan Blette, Lieuwe D Bos, Kevin G Buell, Jonathan D Casey, Carolyn S Calfee, Lorenzo Del Sorbo, Elisa Estenssoro, Niall D Ferguson, Rachel Giblon, Anders Granholm, Ewan C Goligher
Clinicians aim to provide treatments that will result in the best outcome for each patient. Ideally, treatment decisions are based on evidence from randomised clinical trials. Randomised trials conventionally report an aggregated difference in outcomes between patients in each group, known as an average treatment effect. However, the actual effect of treatment on outcomes (treatment response) can vary
-
Correction to Lancet Respir Med 2025; 13: 35–46 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-14
No Abstract
-
The big five vexing questions of respiratory syncytial virus immunisation Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-14 Farina Leonie Shaaban, Louis J Bont
No Abstract
-
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-14 Michael G Ison, Alberto Papi, Eugene Athan, Robert G Feldman, Joanne M Langley, Dong-Gun Lee, Isabel Leroux-Roels, Federico Martinon-Torres, Tino F Schwarz, Richard N van Zyl-Smit, Susanna Cuadripani, Quentin Deraedt, Nancy Dezutter, Catherine Gerard, Laurence Fissette, Stebin Xavier, Marie-Pierre David, Aurélie Olivier, Marie Van der Wielen, Dominique Descamps, Manuel Zocco
BackgroundDuration of protection after respiratory syncytial virus (RSV) vaccination is unknown. This study aimed to evaluate efficacy and safety over three RSV seasons of the AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) against RSV-related lower respiratory tract disease (RSV-LRTD) in older adults. MethodsIn this randomised, observer-blind, placebo-controlled, phase 3 trial
-
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-12 Aoife Leonard, Brian O’Brien, Ian Conrick-Martin, Karen Healy, Alan Gaffney
No Abstract
-
Microplastics: an underestimated and underregulated crisis Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08 Vijay Shankar Balakrishnan
No Abstract
-
Climate change fuels deadly dust storms worldwide Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08 Bryant Furlow
No Abstract
-
Inflammatory risks and asthma attacks: what comes next? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08 Mona Al-Ahmad, Asmaa Ali
No Abstract
-
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-08 Fleur L Meulmeester, Samuel Mailhot-Larouche, Carlos Celis-Preciado, Samuel Lemaire-Paquette, Sanjay Ramakrishnan, Michael E Wechsler, Guy Brusselle, Jonathan Corren, Jo Hardy, Sarah E Diver, Christopher E Brightling, Mario Castro, Nicola A Hanania, David J Jackson, Neil Martin, Annette Laugerud, Emilio Santoro, Chris Compton, Megan E Hardin, Cecile T J Holweg, Simon Couillard
BackgroundClinical risk factors for severe asthma attacks have been identified, but their incremental prognostic values are unclear. Additionally, the incremental contribution of type 2 inflammation, a common, treatable process, is undetermined. We aimed to quantify the prognostic value of baseline characteristics and type 2 inflammatory biomarkers, specifically blood eosinophil count and fractional
-
Pneumonia: a neglected global threat Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-01
No Abstract
-
The weight of air: a Commission on palliative care integration in serious respiratory illness Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-01 William E Rosa, Afsan Bhadelia, Gemma Bowsher, Mark Dransfield, Anand S Iyer, Felicia Marie Knaul, Kathleen Lindell, Matthew Maddocks, Christian Ntizimira, Obianuju Ozoh, Pedro E Pérez-Cruz, Lukas Radbruch, Smriti Rana, Anne-Marie Russell, Mac Skelton, Natasha Smallwood, Samuel Byiringiro, Jeffersson Santos, Donald R Sullivan
No Abstract
-
Correction to Lancet Respir Med 2025; 13: 318–26 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-04-01
Norberg SM, Valdez J, Napier S, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. Lancet Respir Med 2025; 13: 318–26—In this Article, some of the appendix page numbers in the main text and an abbreviation in the tables have been updated, and missing or switched data for patients 8, 10, 11, 12, 13, and 27 in figure 2 have been corrected
-
Targeting neutrophil serine proteases in bronchiectasis—where are we now? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-25 Oleksandr Mazulov
No Abstract
-
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-25 Nan-Shan Zhong, Rong Qiu, Jie Cao, Yan-Ming Huang, Hua Zhou, Xing-Xiang Xu, Jin-Fu Xu, Huan Ye, Zhi-Ren Yang, Ling-Yun Gao, Yao Shen, Zu-Ke Xiao, Shi-Guang Xie, Dian-Jie Lin, Li Zhao, Hao Xiong, Xian-Ming Zhang, Fang-Qiong Li, Wei-Jie Guan, James D Chalmers, James Duncan Chalmers
BackgroundAirway neutrophil inflammation with excessive neutrophil serine proteases is implicated in frequent exacerbations of bronchiectasis. HSK31858 is a novel reversible inhibitor of DPP-1. We aimed to assess the efficacy and safety of HSK31858 in decreasing the frequency of bronchiectasis exacerbations among adults with bronchiectasis. MethodsSAVE-BE was a phase 2, double-blind, randomised, placebo-controlled
-
Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24
BackgroundAsthma and atopic dermatitis are common allergic conditions that contribute to substantial health loss, economic burden, and pain across individuals of all ages worldwide. Therefore, as a component of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we present updated estimates of the prevalence, disability-adjusted life-years (DALYs), incidence, and deaths due
-
Predicting the future global burden of asthma and atopic dermatitis: identifying strategies for prevention Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24 Erik Melén, Judith Garcia-Aymerich
No Abstract
-
Addressing the growing TB disease burden in England Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24 Kerry A Millington, Rebecca Nightingale, Naomi F Walker, Beate Ringwald, Daire Cantillon, Fatima Karmadwala, Tom Wingfield
No Abstract
-
Unveiling a hidden phenotype of early tuberculosis Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24 Joanna Ehrlich, Clara Suñer, Gavin Churchyard, Frank Cobelens, Mark Hatherill, Simon C Mendelsohn, Kristin N Nelson, Tom Scriba, Grant Theron, Leonardo Martinez, Alberto L Garcia-Basteiro
No Abstract
-
End of USAID leaves enormous funding shortfall for TB Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-24 Talha Burki
No Abstract
-
The importance of post-tuberculosis morbidity in high-income countries Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22 Ailva O’Reilly, Dominik Zenner, Pranabashis Haldar, Samara Barnes, Jamilah Meghji, Manish Pareek
No Abstract
-
Transition of adolescents with asthma to adult care Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22 Priya Venkatesan
No Abstract
-
Post-tuberculosis lung disease: towards prevention, diagnosis, and care Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22 Jamilah Meghji, Sara C Auld, Gregory P Bisson, Celso Khosa, Refiloe Masekela, Neelima Navuluri, Andrea Rachow
There is a growing body of data describing the high burden of respiratory sequelae seen among tuberculosis survivors, including children, adolescents, and adults. This group of sequelae are known as post-tuberculosis lung disease and include parenchymal damage, airway disease, and pulmonary vascular disease. It is thought that approximately half of pulmonary tuberculosis survivors have ongoing structural
-
Equitable, personalised medicine for tuberculosis: treating patients, not diseases Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-22 Lorenzo Guglielmetti, Samiran Panda, Amanzhan Abubakirov, Naseem Salahuddin, Christophe Perrin, Carole D Mitnick
No Abstract
-
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21 Tyler Pitre, Winnie Liu, Dena Zeraatkar, Jonathan D Casey, Joanna C Dionne, Kevin W Gibbs, Adit A Ginde, Natalie Needham-Nethercott, Todd W Rice, Matthew W Semler, Bram Rochwerg
BackgroundPreoxygenation is a crucial preparatory step for intubation. Several strategies for preoxygenation exist, including facemask oxygen, high-flow nasal cannula (HFNC), and non-invasive positive pressure ventilation (NIPPV). However, the comparative efficacy of these strategies remains largely uncertain. We aimed to compare the efficacy and safety of HFNC, NIPPV, and facemask oxygen for preoxygenation
-
Nasal high-flow oxygen for apnoeic oxygenation during emergency endotracheal intubation of children Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21 Emma C Alexander, Padmanabhan Ramnarayan
No Abstract
-
Preoxygenation for tracheal intubation in adults who are critically ill: time to abandon the facemask? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21 Sheila Nainan Myatra, Samir Jaber
No Abstract
-
Effectiveness of nasal high-flow oxygen during apnoea on hypoxaemia and intubation success in paediatric emergency and ICU settings: a randomised, controlled, open-label trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-21 Shane George, Tara Williams, Susan Humphreys, Tiffany Atkins, David Tingay, Ben Gelbart, Trang Pham, Simon Craig, Simon Erickson, Arjun Chavan, Katie Rasmussen, Anusha Ganeshalingham, Felix Oberender, Subodh Ganu, Nitesh Singhal, Kristen Gibbons, Renate Le Marsney, Juerg Burren, Luregn J Schlapbach, Brenda Gannon, Andreas Schibler
BackgroundThe use of nasal high-flow (NHF) oxygen for apnoeic oxygenation during emergency paediatric intubation is not universally adopted. Although previous studies suggest potential benefits, it remains unclear whether NHF enhances the likelihood of achieving successful first-attempt intubation without oxygen desaturation in children. We aimed to investigate whether the provision of NHF oxygen during
-
The bidirectional complexity of multiple long-term conditions and post-COVID-19 condition Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-18 Kamlesh Khunti, Rachael A Evans, Amitava Banerjee, Christina van der Feltz-Cornelis
No Abstract
-
Positive airway pressure and all-cause and cardiovascular mortality in people with obstructive sleep apnoea Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-18 Ye Zhang, Virend K Somers, Xiangdong Tang
No Abstract
-
Positive airway pressure therapy and all‐cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-18 Adam V Benjafield, Jean-Louis Pepin, Peter A Cistulli, Alison Wimms, Florent Lavergne, Fatima H Sert Kuniyoshi, Sibyl H Munson, Brendan Schuler, Shrikar Reddy Badikol, Kelly C Wolfe, Leslee Willes, Colleen Kelly, Tetyana Kendzerska, Dayna A Johnson, Raphael Heinzer, Chi-Hang Lee, Atul Malhotra
BackgroundData regarding the effect of positive airway pressure (PAP) therapy for obstructive sleep apnoea (OSA) on all-cause mortality are inconsistent. We aimed to conduct a systematic review and meta-analysis to test the hypothesis that PAP therapy is associated with reduced all-cause and cardiovascular mortality in people with OSA. MethodsFor this systematic review and meta-analysis, we searched
-
Withdrawal of life sustaining therapies in patients with or without acute brain injury Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-17 Scott R DeBoer, Romergryko Geocadin
No Abstract
-
Decisions to withdraw or withhold life-sustaining therapies in patients with and without acute brain injury: a secondary analysis of two prospective cohort studies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-17 Shaurya Taran MD, Kuan Liu PhD, Victoria A McCredie MBChB, Oscar Penuelas MD, Prof Karen E A Burns MD, Fernando Frutos-Vivar MD, Prof Damon C Scales MD, Prof Niall D Ferguson MD, Jeffrey M Singh MD, Armaan K Malhotra MD, Neill K J Adhikari MDCM
Many deaths in the intensive care unit (ICU) occur after a decision to withdraw or withhold life-sustaining therapies (WLSTs). We aimed to explore the differences in the incidence and timing of WLST between patients with and without acute brain injuries (ABIs).
-
An overview of influenza H5 vaccines Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-13 Jessica Taaffe, Shuyi Zhong, Shoshanna Goldin, Kate S Rawlings, Benjamin J Cowling, Wenqing Zhang
No Abstract
-
Placebo responses in clinical trials of refractory chronic cough: mechanisms, challenges, and mitigation strategies Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-12 Elena Kum, Wafa Hassan, Imran Satia
No Abstract
-
Home-based monitoring in chronic respiratory diseases: in search of Panacea Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-04 Nicolas Roche, Kerri A Johannson
No Abstract
-
Correction to Lancet Respir Med 2025; 13: 244–55 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-04
Hoppe JE, Kasi AS, Pittman JE, et al. Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med 2025; 13: 244–55—The author line of this Article should have included the VX21-121-105 Study Group. This correction has been made to the online version as of March 4, 2025, and the
-
Correction to Lancet Respir Med 2025; 13: 256–71 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-04
Keating C, Yonker LM, Vermeulen F, et al. Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med 2025; 13: 256–71—The author line of this Article should have included the VX20-121-102 Study
-
Correction to Lancet Respir Med 2025; 13: 208–20 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-03-04
Castro M, Papi A, Porsbjerg C, et al. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med 2025; 13: 208–20—In the Summary Methods section of this Article, the fourth sentence should have read “Randomisation was stratified by inhaled corticosteroids
-
Measles outbreak challenges Trump's public health vision Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-26 Bryant Furlow
No Abstract
-
Perioperative lung expansion and pulmonary outcomes after abdominal surgery Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-25 Randal S Blank, Hyun Joo Ahn
No Abstract
-
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-25 Ana Fernandez-Bustamante, Robert A Parker, Gyorgy Frendl, Jae Woo Lee, Alexander Nagrebetsky, Loreta Grecu, David Amar, Pedro Tanaka, Juraj Sprung, Ravindra A Gupta, Balachundhar Subramanian, Jadelis Giquel, Matthias Eikermann, Guido Musch, Jacob W Nadler, Marcelo Gama de Abreu, Karsten Bartels, Meera Grover, Lee-Lynn Chen, Jamie Sparling, Marcos F. Vidal Melo
BackgroundPostoperative pulmonary complications (PPCs) are a leading cause of morbidity, death, and increased use of health-care resources. We aimed to determine whether a perioperative lung expansion bundle including individualised intraoperative management reduces PPC severity in patients undergoing major open abdominal surgery compared with usual care. MethodsIn this multicentre, randomised controlled
-
In-hospital outcomes and 6-month follow-up results of patients supported with extracorporeal membrane oxygenation for COVID-19 from the second wave to the end of the pandemic (EuroECMO-COVID): a prospective, international, multicentre, observational study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-23 Maria Elena De Piero MD, Silvia Mariani MD, Bas C T van Bussel PhD, Dominik Jarczak MD, Niklas Krenner PhD, Prof Enrique Perez de la Sota MD, Pedro E Silva MD, Magdalena Roemmer MD, Mariusz Kowalewski PhD, Simone Carelli MD, Lars Mikael Broman PhD, Alain Vuylsteke MD, Philip Fortuna MD, Francesco Alessandri MD, Gennaro Martucci PhD, Brijesh V Patel PhD, Gosta Lotz MD, Prof Udo Boeken PhD, Sven Maier
Extracorporeal membrane oxygenation (ECMO) for COVID-19 was thoroughly assessed during the first pandemic wave, but data on subsequent waves are limited. We aimed to investigate in-hospital and 6-month survival of patients with COVID-19 supported with ECMO from the second pandemic wave (Sept 15, 2020) until the end of the pandemic (March 21, 2023, announced by WHO).
-
Long-term outcomes and the future of extracorporeal care Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-23 J W Awori Hayanga, Heather Kaiser Hayanga
No Abstract
-
Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-20 Franck F Rahaghi MD MHS, Marc Humbert MD PhD, Marius M Hoeper MD, R James White MD PhD, Robert P Frantz MD, Paul M Hassoun MD, Anna R Hemnes MD, Steven M Kawut MD, Vallerie V McLaughlin MD, Gergely Meszaros JD MSc, Peter G M Mol PhD, Steven D Nathan MD, Mitchel A Psotka MD PhD, Farbod N Rahaghi MD MHS, Olivier Sitbon MD PhD, Norman Stockbridge MD PhD, Jason Weatherald MD, Faiez Zannad MD PhD, Sandeep
Novel treatments in pulmonary arterial hypertension (PAH) with significant pathophysiological and clinical responses have generated renewed interest in changing the course of the disease and achieving long-term disease control. Historically, the term disease modification was coined in rheumatological conditions with therapies that managed to treat the underlying condition as opposed to just alleviating
-
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-14 Tony Kirby
No Abstract
-
Use of lung-cancer trends for global and public health priorities Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-14 Eunji Choi, Julie A Barta
No Abstract
-
Spirometry—one size doesn't fit all Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-14 The Lancet Respiratory Medicine
No Abstract
-
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-12 Tony Kirby
No Abstract
-
Epidemiology and management of paediatric pulmonary embolism: a much-needed focus of research Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-12 Kaiyuan Zhen, Peiran Yang, Zhenguo Zhai
No Abstract
-
Historic TB outbreak a wake-up call for US policy makers Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-12 Bryant Furlow
No Abstract
-
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-10 Prof Mario Castro MD, Prof Alberto Papi MD, Prof Celeste Porsbjerg MD, Njira L Lugogo MD, Prof Christopher E Brightling FRCP, Francisco-Javier González-Barcala MD, Prof Arnaud Bourdin MD, Mykola Ostrovskyy MD, Maria Staevska MD, Pai-Chien Chou MD, Liliana Duca MD, Ana Margarida Pereira MD, Charles Fogarty MD, Rufai Nadama FRCP, Mei Zhang PhD, Amelie Rodrigues MSc, Xavier Soler MD, Harry J Sacks MD
Asthma is a respiratory disease characterised by chronic airway inflammation and mucus hypersecretion. VESTIGE used functional respiratory imaging to assess changes in airway structure and function, including mucus plugging, in response to dupilumab.
-
Management and mechanisms of eosinophil action in asthma: mind the gap? Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-10 Richard E K Russell
No Abstract
-
Acute pulmonary embolism in children and adolescents in the USA (2016 and 2019): a nationwide retrospective cohort study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04 Simon Wolf, Luca Valerio, Nils Kucher, Stavros V Konstantinides, Irene L M Klaassen, C Heleen van Ommen, Cihan Ay, Frederikus A Klok, Suzanne C Cannegieter, Stefano Barco
BackgroundEpidemiological data on acute pulmonary embolism among children and adolescents are sparse and only date back to the 2000s. We aimed to establish annual estimates and age-stratified and sex-stratified indicators of acute pulmonary embolism among children and adolescents aged 0–19 years. MethodsWe did a retrospective, nationwide, patient-level analysis of the Kids’ Inpatient Database, including
-
PH and CKD: unravelling the cardiorenal nexus Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04 Faeq Husain-Syed, Uta Erdbrügger, Susmita Sahoo, Thorsten Wiech, Claudio Ronco, Khodr Tello
No Abstract
-
Expanding CFTR modulator access to benefit all patients who are waiting for a lung transplant Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04 Rossa Brugha, Kavita Dave, Vicky Gerovasili, Amit Adlakha
No Abstract
-
Thank you to The Lancet Respiratory Medicine's clinical and statistical peer reviewers in 2024 Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-04
No Abstract
-
Treatment strategy for EGFR mutated NSCLC Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-03 Yusuke Okuma
No Abstract
-
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-03 Prof Yuankai Shi MD, Prof Yanzhen Guo BS, Prof Xingya Li PhD, Lin Wu MD, Prof Zhaohong Chen MM, Sheng Yang MD, Prof Minghong Bi MM, Yanqiu Zhao MD, Prof Wenxiu Yao MD, Huiqing Yu BS, Prof Ke Wang MD, Prof Wenhua Zhao MD, Prof Meili Sun PhD, Prof Liangming Zhang PhD, Prof Zhiyong He BS, Yingcheng Lin MM, Jianhua Shi MD, Prof Bo Zhu MD, Prof Lijun Wang BS, Prof Yueyin Pan MD, Prof Huaqiu Shi MM, Prof
This study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC).
-
Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study Lancet Respir. Med. (IF 38.7) Pub Date : 2025-02-03 Ganfeng Luo PhD, Yanting Zhang PhD, Harriet Rumgay PhD, Eileen Morgan PhD, Oliver Langselius MSc, Jerome Vignat MSc, Murielle Colombet MSc, Freddie Bray PhD
Lung cancer is the most common cancer worldwide, yet the current epidemiological profile of lung-cancer incidence by histological subtype is only partly understood. We aimed to assess geographical variation in incidence of lung cancer by subtype worldwide in 2022, geographical variation in adenocarcinoma incidence attributable to ambient particulate matter (PM) pollution worldwide in 2022, temporal
更新日期：2025-04-09
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号